What had actually been held apart
The proposed model had a development set and an assessment set, and the counts reconciled. There were 240 fictional specimens from forty batches, with six specimens in each batch. The initial allocation placed 180 specimens in development and sixty in assessment. It was easy to describe that as an evaluation on unseen observations. The phrase was technically appealing and commercially useful. It did not, however, tell us whether the assessment represented the situation in which the product was intended to be used: a new batch whose shared conditions had not appeared in development.
Thirty of the batches contributed specimens to both sides. Each supplied four development specimens and two assessment specimens. Ten other batches supplied all six specimens to development. That arrangement accounted for every row, but a related group of observations remained present across the boundary. A different specimen can carry information about conditions shared with specimens the model has already encountered. If the business decision concerns a new batch, the organisation needs to examine that relationship before it presents the assessment as evidence of the proposed capability.
I do not regard a grouped split as an answer that should be imposed without context. Some applications genuinely concern another observation within familiar conditions. Others concern a future period, a different site or a new population, each with its own complications. The first question is what must be unfamiliar for the assessment to be relevant. The technical team should be able to explain that choice in terms the decision owner understands. A partition is part of the argument about use, not simply a preparatory step completed before the interesting model work begins.
In this case, Imran asked us to retain the distinction between a new specimen and a new batch. The commercial proposal depended on the latter. That made the original assessment insufficient for the claim under discussion, even though the held-out specimens were separate physical observations. We needed a new design. The finding did not prove that the model was useless or that every earlier calculation was invalid. It showed that the evidence we had prepared did not yet answer the question the proposed product needed to answer.
The commercial cost of a better question
The team had already invested in the original workflow. Commercial colleagues had planned a product discussion around the assessment, and they were understandably reluctant to replace a completed result with a request for further work. They also asked whether a smaller development set would make the model weaker. Those were legitimate concerns. A better evaluation can use resources differently and may reveal a less attractive result. I did not want the discussion to imply that methodological care is free or that the corrected design would necessarily improve the commercial story.
We reassigned complete batches. Twenty-six batches, containing 156 specimens, were used for development. Fourteen batches, containing eighty-four specimens, were held apart. The allocation made the batch boundary explicit. It was not a claim that these particular counts are universally sufficient or that this ratio is the right choice for every application. The responsible analytical team still needed to assess the available evidence, the intended use and the variability within it. A more appropriate separation removes one concern; it does not complete every part of model evaluation.
The revised programme required ₹45 lakh, with a further ₹7 lakh annual review provision. Those are fictional expenses, not savings or a valuation of avoided harm. We accepted the work without knowing whether the eventual assessment would strengthen the product case. The earlier metric was no longer used to support the planned launch account. I think that consequence matters in an executive narrative. It is easy to endorse better evidence after it delivers a favourable result. The actual decision was to delay the account we could already tell in order to find out whether a different account was justified.
The separation also had to survive the rest of the analytical workflow. If information from the held-apart observations shapes preprocessing or model choices, the boundary can be weakened even when the initial allocation is sound. I do not present a complete modelling procedure here. I want the responsible specialists to explain how their workflow protects the assessment question they have chosen. A senior data role should connect that explanation with the commercial claim, so that the business does not continue selling one kind of evidence while the technical team is evaluating another.
Evidence that remains relevant after the demonstration
A demonstration can make a model look self-contained. There is an input, an output and a number that appears to summarise performance. The enterprise then needs to decide where that evidence applies. Does the intended population resemble the development record? Which conditions were excluded? What kinds of observations may arrive later? Who can stop or narrow the use when those conditions change? Those questions are not a reason to reject every analytical product. They are part of understanding what the product is, especially when its apparent precision can outlast the circumstances that supported it.
I want a model proposal to state its intended decision before its preferred metric. The decision determines which mistakes matter and what kind of unfamiliarity the evaluation needs to represent. That statement should also distinguish support for a qualified professional from an automated conclusion the product is not authorised to issue. In a materials-evidence practice, a predictive output does not become a building approval or a substitute for the required technical assessment simply because it is presented confidently. The responsible owner and the application boundary remain part of the product's operating account.
For a board, the useful challenge concerns the match between evidence and commercial commitment. Directors can ask what was genuinely held apart, why that choice resembles the intended use and what remains uncertain. They should hear what would make management pause, not only what would permit a launch. They do not need to select every modelling technique. Their role is to understand whether the enterprise's claims and resources are proportionate to what has been demonstrated, including the expense of maintaining relevant evidence as the use and the incoming observations change.
The case also affects how I describe an unsuccessful or delayed proposal. A revised assessment might eventually support a narrower use, require more evidence or make the product unattractive. Any of those outcomes would be more informative than retaining a metric whose meaning did not match the decision. I would not call the expense wasted simply because it removed a planned claim. Equally, I would not call it a success without explaining what the work actually established. The leadership account should preserve that uncertainty rather than manufacture a later score to reward the decision retrospectively.
The question I carry forward is simple enough for an executive discussion: what did the assessment encounter that the real decision will not already know? The answer may lead to batches, sites, periods or another relevant unit. It must come from the use case, with the technical team able to defend it. A new row can be unfamiliar in one sense and familiar in another. I want the enterprise to understand that difference before it treats an evaluation result as permission to make a broader promise than the evidence can support.